CRNX

39.77

0.05% 0.02

Dopo l'orario di chiusura: 39.77

Crinetics Pharmaceuticals Inc (CRNX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché CRNX Giù? Forum Previsione

Precedente Chiudi:

$39.75

Aprire:

$39.63

Volume 24 ore:

739.80K

Relative Volume:

0.68

Capitalizzazione di mercato:

$4.16B

Reddito:

$7.70M

Utile/perdita netta:

$-465.32M

Rapporto P/E:

-8.0431

EPS:

-4.9446

Flusso di cassa netto:

$-383.68M

1 W Prestazione:

-0.48%

1M Prestazione:

+6.08%

6M Prestazione:

-9.92%

1 anno Prestazione:

+34.09%

Intervallo 1D:

$38.99

$40.03

Intervallo di 1 settimana:

$38.25

$40.44

Portata 52W:

$25.83

$57.99

Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile

Nome

Crinetics Pharmaceuticals Inc

Settore

Healthcare (1112)

Industria

Biotechnology (621)

Telefono

858-450-6464

Indirizzo

6055 LUSK BLVD., SAN DIEGO, CA

Dipendente

594

Cinguettio

@Crinetics

Prossima data di guadagno

2024-11-12

Ultimi documenti SEC

CRNX's Discussions on Twitter

Compare CRNX vs VRTX, REGN, ARGX, ALNY, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
CRNX Crinetics Pharmaceuticals Inc	39.77	4.16B	7.70M	-465.32M	-383.68M	-4.9446
VRTX Vertex Pharmaceuticals Inc	441.70	113.01B	12.07B	3.95B	3.19B	15.33
REGN Regeneron Pharmaceuticals Inc	753.93	79.87B	14.34B	4.50B	3.77B	41.56
ARGX Argen X Se Adr	840.87	51.51B	4.16B	1.29B	734.26M	19.58
ALNY Alnylam Pharmaceuticals Inc	333.39	45.29B	3.71B	313.75M	465.38M	2.2571
ONC Beone Medicines Ltd Adr	319.94	34.41B	5.36B	287.73M	924.18M	2.5229

Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-01-12	Aggiornamento	Goldman	Neutral → Buy
2025-07-10	Iniziato	Goldman	Neutral
2025-03-25	Iniziato	Stifel	Buy
2025-02-11	Iniziato	TD Cowen	Buy
2025-02-04	Iniziato	Wolfe Research	Peer Perform
2025-01-22	Aggiornamento	Jefferies	Hold → Buy
2024-03-06	Iniziato	Citigroup	Buy
2024-01-16	Iniziato	Morgan Stanley	Overweight
2023-12-21	Iniziato	Jefferies	Hold
2023-11-20	Ripresa	JP Morgan	Overweight
2023-10-24	Ripresa	Cantor Fitzgerald	Overweight
2023-08-31	Iniziato	Oppenheimer	Outperform
2023-04-24	Iniziato	Piper Sandler	Overweight
2023-03-30	Iniziato	Robert W. Baird	Outperform
2021-11-30	Iniziato	JMP Securities	Mkt Outperform
2021-11-23	Iniziato	Evercore ISI	Outperform
2021-06-18	Aggiornamento	JP Morgan	Neutral → Overweight
2019-12-23	Iniziato	ROTH Capital	Buy
2019-02-14	Iniziato	H.C. Wainwright	Buy
2018-08-13	Iniziato	JP Morgan	Neutral
2018-08-13	Iniziato	Leerink Partners	Outperform
2018-08-13	Iniziato	Piper Jaffray	Overweight

Mostra tutto

Crinetics Pharmaceuticals Inc Borsa (CRNX) Ultime notizie

02:00 AM

Neutrolis Appoints Caren Deardorf as Chief Business & Strategy Officer - GlobeNewswire Inc.

02:00 AM

Apr 14, 2026

CRNX (NASDAQ: CRNX) files Rule 144: 20,900-share exercise, prior 10b5-1 sales - Stock Titan

Apr 14, 2026

Apr 13, 2026

Insider Sales: CRNX (NASDAQ: CRNX) 4,434-share option sale; Knight 95,074 prior shares - Stock Titan

Apr 13, 2026

(CRNX) Volatility Zones as Tactical Triggers - Stock Traders Daily

Apr 13, 2026

Fed Meeting: Is Crinetics Pharmaceuticals Inc stock a top performer YTD2026 Rallies & Free Real-Time Market Sentiment Alerts - baoquankhu1.vn

Apr 13, 2026

Apr 12, 2026

Indivior, Liquidia, Crinetics top Quant pharma list as Merck scoops up Terns for $6.7B - MSN

Apr 12, 2026

Apr 11, 2026

Crinetics Pharmaceuticals Signs Independent Consultant Agreement with Jeff Knight – 8-K Filing Details and XBRL Information - Minichart

Apr 11, 2026

Apr 10, 2026

Crinetics Pharma chief dev officer sells $3.4m in stock By Investing.com - Investing.com Canada

Apr 10, 2026

Crinetics Pharmaceuticals Insider Sold Shares Worth $3,415,036, According to a Recent SEC Filing - marketscreener.com

Apr 10, 2026

Crinetics (CRNX) COO exercises options and sells 85,163 shares under 10b5-1 - Stock Titan

Apr 10, 2026

Jeff Knight exits Crinetics (NASDAQ: CRNX) officer role, stays on under paid consulting deal - Stock Titan

Apr 10, 2026

Apr 09, 2026

Crinetics Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026 - Sahm

Apr 09, 2026

A Look At Crinetics Pharmaceuticals (CRNX) Valuation After Brazil ANVISA Filing For PALSONIFY - Sahm

Apr 09, 2026

Crinetics Pharmaceuticals to Report Q1 2026 Results on May 7 - National Today

Apr 09, 2026

Apr 08, 2026

Aug Retail: Whats the beta of Crinetics Pharmaceuticals Inc stock2026 Major Catalysts & Precise Buy Zone Identification - baoquankhu1.vn

Apr 08, 2026

Insider sale: CRNX (NASDAQ: CRNX) files Form 144 for 9,911 shares on 03/16/2026 - Stock Titan

Apr 08, 2026

Crinetics sets May 7 earnings call, business update after close - Stock Titan

Apr 08, 2026

Apr 07, 2026

Aug Shorts: Is Crinetics Pharmaceuticals Inc a stock for growth or value investors2026 Recap & Trade Opportunity Analysis Reports - baoquankhu1.vn

Apr 07, 2026

Future of Pituitary Cancer Market (2026-2033) | Precision - openPR.com

Apr 07, 2026

Apr 06, 2026

Risk Hedge: Is Crinetics Pharmaceuticals Inc exposed to currency risks2026 Market WrapUp & AI Powered Buy/Sell Recommendations - baoquankhu1.vn

Apr 06, 2026

Why Crinetics Pharmaceuticals (CRNX) Is Up 10.6% After Brazil PALSONIFY Filing Expands Global Footprint - Sahm

Apr 06, 2026

Apr 05, 2026

Aberdeen Group plc Buys 334,584 Shares of Crinetics Pharmaceuticals, Inc. $CRNX - MarketBeat

Apr 05, 2026

Apr 04, 2026

Price performance - Yahoo Finance Australia

Apr 04, 2026

Apr 02, 2026

Crinetics Pharmaceuticals Inc (6Z4.DU) stock price, news, quote and history - Yahoo Finance UK

Apr 02, 2026

Price-Driven Insight from (CRNX) for Rule-Based Strategy - Stock Traders Daily

Apr 02, 2026

CRNX Stock Price, Quote & Chart | CRINETICS PHARMACEUTICALS IN (NASDAQ:CRNX) - ChartMill

Apr 02, 2026

Apr 01, 2026

Crinetics Director Sells 5,000 Shares With Stock Down 4%, but Here's What Matters More - AOL.com

Apr 01, 2026

Mar 31, 2026

Crinetics Pharmaceuticals Director Sells Shares - intellectia.ai

Mar 31, 2026

Mar 30, 2026